Brief: Ultimovacs Provides Phase II NIPU Results

Zelluna ASA

23/10/2023 06:11

Oct 23 (Reuters) - Ultimovacs ASA  ULTI.OL :
    * COMPLETE PHASE II NIPU RESULTS: SIGNIFICANT AND CLINICALLY
MEANINGFUL IMPROVEMENT IN OVERALL SURVIVAL FOR PATIENTS WITH
MALIGNANT MESOTHELIOMA RECEIVING UV1 CANCER VACCINE
    * NO ADDITIONAL SAFETY CONCERNS WERE REPORTED FROM UV1
TREATMENT.
    * RESULTS SHOWED THAT ULTIMOVACS' CANCER VACCINE UV1, IN
COMBINATION WITH IPILIMUMAB AND NIVOLUMAB, DEMONSTRATED
IMPROVEMENT IN OVERALL SURVIVAL VERSUS IPILIMUMAB AND NIVOLUMAB
ALONE, KEY SECONDARY ENDPOINT

Source text for Eikon:  ID:nGNEb8gl8v 
Further company coverage:  ULTI.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))